Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672021 · ClinicalTrials.gov registry record · NA
Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT01672021 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 80 participants.
The verdict
NCT01672021, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Because MRI can provide increased brain and liver lesion detection as compared with CT, the investigators hypothesize that FDG-PET/MRI will provide concordant or improved lesion detection as compared with FDG-PET/CT in breast cancer patients at a decreased radiation dose.
Interventions
- PROCEDURE PET/MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2012-07 |
| Est. Completion | 2021-10-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672021
The ClinicalTrials.gov registry entry for NCT01672021 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PET/MRI is the first listed.
NCT01672021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672021 about?
NCT01672021 is a clinical study titled "Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients". Because MRI can provide increased brain and liver lesion detection as compared with CT, the investigators hypothesize that FDG-PET/MRI will provide concordant or improved lesion detection as compared with FDG-PET/CT in breast cancer patients at a decreased radiation dose.
What is the current status of trial NCT01672021?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2012-07. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT01672021?
The interventions under investigation include: PET/MRI (PROCEDURE).
Who is sponsoring clinical trial NCT01672021?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.